Last reviewed · How we verify

Cancer Trials Ireland — Portfolio Competitive Intelligence Brief

Cancer Trials Ireland pipeline: 1 marketed, 0 filed, 1 Phase 3, 4 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 1 Phase 3 4 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Dexamethasone (IV) Dexamethasone (IV) marketed Glucocorticoid (corticosteroid) Glucocorticoid receptor (GR) Oncology, Immunology, Inflammation
Cisplatin / Oxaliplatin Cisplatin / Oxaliplatin phase 3 Platinum-based chemotherapy agent DNA Oncology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Merck Sharp & Dohme LLC · 2 shared drug classes
  2. Biocad · 1 shared drug class
  3. Federation Francophone de Cancerologie Digestive · 1 shared drug class
  4. Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno · 1 shared drug class
  5. Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 1 shared drug class
  6. Chinese Academy of Medical Sciences · 1 shared drug class
  7. Celgene · 1 shared drug class
  8. Amgen · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Cancer Trials Ireland:

Cite this brief

Drug Landscape (2026). Cancer Trials Ireland — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/cancer-trials-ireland. Accessed 2026-05-16.

Related